Literature DB >> 19458356

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.

Alejandro Gutierrez1, Takaomi Sanda, Ruta Grebliunaite, Arkaitz Carracedo, Leonardo Salmena, Yebin Ahn, Suzanne Dahlberg, Donna Neuberg, Lisa A Moreau, Stuart S Winter, Richard Larson, Jianhua Zhang, Alexei Protopopov, Lynda Chin, Pier Paolo Pandolfi, Lewis B Silverman, Stephen P Hunger, Stephen E Sallan, A Thomas Look.   

Abstract

To more comprehensively assess the pathogenic contribution of the PTEN-PI3K-AKT pathway to T-cell acute lymphoblastic leukemia (T-ALL), we examined diagnostic DNA samples from children with T-ALL using array comparative genomic hybridization and sequence analysis. Alterations of PTEN, PI3K, or AKT were identified in 47.7% of 44 cases. There was a striking clustering of PTEN mutations in exon 7 in 12 cases, all of which were predicted to truncate the C2 domain without disrupting the phosphatase domain of PTEN. Induction chemotherapy failed to induce remission in 3 of the 4 patients whose lymphoblasts harbored PTEN deletions at the time of diagnosis, compared with none of the 12 patients with mutations of PTEN exon 7 (P = .007), suggesting that PTEN deletion has more adverse therapeutic consequences than mutational disruptions that preserve the phosphatase domain. These findings add significant support to the rationale for the development of therapies targeting the PTEN-PI3K-AKT pathway in T-ALL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458356      PMCID: PMC2713461          DOI: 10.1182/blood-2009-02-206722

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

2.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

Review 3.  PTEN function in normal and neoplastic growth.

Authors:  Lionel M L Chow; Suzanne J Baker
Journal:  Cancer Lett       Date:  2006-01-18       Impact factor: 8.679

4.  Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.

Authors:  Hagen Graf Einsiedel; Arend von Stackelberg; Reinhard Hartmann; Rüdiger Fengler; Martin Schrappe; Gritta Janka-Schaub; Georg Mann; Karel Hählen; Ulrich Göbel; Thomas Klingebiel; Wolf-Dieter Ludwig; Günter Henze
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

5.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas.

Authors:  Keisuke Kurose; Kristie Gilley; Satoshi Matsumoto; Peter H Watson; Xiao-Ping Zhou; Charis Eng
Journal:  Nat Genet       Date:  2002-10-15       Impact factor: 38.330

6.  K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements.

Authors:  Der-Cherng Liang; Lee-Yung Shih; Jen-Fen Fu; Huei-Ying Li; Hsiu-I Wang; Iou-Jih Hung; Chao-Ping Yang; Tang-Her Jaing; Shu-Huey Chen; Hsi-Che Liu
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

7.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

Authors:  A J Philp; I G Campbell; C Leet; E Vincan; S P Rockman; R H Whitehead; R J Thomas; W A Phillips
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

8.  RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.

Authors:  J P Perentesis; S Bhatia; E Boyle; Y Shao; X Ou Shu; M Steinbuch; H N Sather; P Gaynon; W Kiffmeyer; J Envall-Fox; L L Robison
Journal:  Leukemia       Date:  2004-04       Impact factor: 11.528

Review 9.  Adult acute lymphoblastic leukaemia.

Authors:  Renato Bassan; Gemma Gatta; Carlo Tondini; Roel Willemze
Journal:  Crit Rev Oncol Hematol       Date:  2004-06       Impact factor: 6.312

10.  Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.

Authors:  Marco Tartaglia; Simone Martinelli; Giovanni Cazzaniga; Viviana Cordeddu; Ivano Iavarone; Monica Spinelli; Chiara Palmi; Claudio Carta; Andrea Pession; Maurizio Aricò; Giuseppe Masera; Giuseppe Basso; Mariella Sorcini; Bruce D Gelb; Andrea Biondi
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  190 in total

1.  Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.

Authors:  Chong Zhang; Yong-Ku Ryu; Taylor Z Chen; Connor P Hall; Daniel R Webster; Min H Kang
Journal:  Leuk Res       Date:  2011-12-03       Impact factor: 3.156

2.  A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Naval Daver; Yanis Boumber; Hagop Kantarjian; Farhad Ravandi; Jorge Cortes; Michael E Rytting; Jitesh D Kawedia; Jordan Basnett; Kirk S Culotta; Zhihong Zeng; Hongbo Lu; Mary Ann Richie; Rebecca Garris; Lianchun Xiao; Wenbin Liu; Keith A Baggerly; Elias Jabbour; Susan O'Brien; Jan Burger; Linda J Bendall; Deborah Thomas; Marina Konopleva
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

3.  DEGAS: de novo discovery of dysregulated pathways in human diseases.

Authors:  Igor Ulitsky; Akshay Krishnamurthy; Richard M Karp; Ron Shamir
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

4.  ATP Binding Cassette C1 (ABCC1/MRP1)-mediated drug efflux contributes to disease progression in T-lineage acute lymphoblastic leukemia.

Authors:  Stuart S Winter; Jerec Ricci; Li Luo; Debbie M Lovato; Hadya M Khawaja; Tasha Serna-Gallegos; Natalie Debassige; Richard S Larson
Journal:  Health (Irvine Calif)       Date:  2013-05

5.  An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.

Authors:  Birgit Knoechel; Justine E Roderick; Kaylyn E Williamson; Jiang Zhu; Jens G Lohr; Matthew J Cotton; Shawn M Gillespie; Daniel Fernandez; Manching Ku; Hongfang Wang; Federica Piccioni; Serena J Silver; Mohit Jain; Daniel Pearson; Michael J Kluk; Christopher J Ott; Leonard D Shultz; Michael A Brehm; Dale L Greiner; Alejandro Gutierrez; Kimberly Stegmaier; Andrew L Kung; David E Root; James E Bradner; Jon C Aster; Michelle A Kelliher; Bradley E Bernstein
Journal:  Nat Genet       Date:  2014-03-02       Impact factor: 38.330

6.  Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.

Authors:  Takaomi Sanda; Xiaoyu Li; Alejandro Gutierrez; Yebin Ahn; Donna S Neuberg; Jennifer O'Neil; Peter R Strack; Christopher G Winter; Stuart S Winter; Richard S Larson; Harald von Boehmer; A Thomas Look
Journal:  Blood       Date:  2009-12-09       Impact factor: 22.113

7.  Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.

Authors:  Michael G Kharas; Rachel Okabe; Jared J Ganis; Maricel Gozo; Tulasi Khandan; Mahnaz Paktinat; D Gary Gilliland; Kira Gritsman
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

8.  Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.

Authors:  Shuyun Rao; Kathy Q Cai; Jason E Stadanlick; Noa Greenberg-Kushnir; Nehal Solanki-Patel; Sang-Yun Lee; Shawn P Fahl; Joseph R Testa; David L Wiest
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

9.  Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis.

Authors:  Catherine Hartzell; Olga Ksionda; Ed Lemmens; Kristen Coakley; Ming Yang; Monique Dail; Richard C Harvey; Christopher Govern; Jeroen Bakker; Tineke L Lenstra; Kristin Ammon; Anne Boeter; Stuart S Winter; Mignon Loh; Kevin Shannon; Arup K Chakraborty; Matthias Wabl; Jeroen P Roose
Journal:  Sci Signal       Date:  2013-03-26       Impact factor: 8.192

Review 10.  Oncogenic PTEN functions and models in T-cell malignancies.

Authors:  M Tesio; A Trinquand; E Macintyre; V Asnafi
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.